"当前创新药销售费用中，基本医保承担44%，商业保险承担7%，其余近半数需由患者自费或通过其他 途径解决。"国家医疗保障局医药管理司司长黄心宇在医保目录解读会上公布的这组数据，直指创新药 支付端的现实痛点。 2026年以来，创新药产业迎来政策密集赋能，支付体系优化与药品可及性提升的双重利好同步落地，国 家打通创新药落地"最后一公里"的力度空前。1月1日，2025年新版国家医保药品目录与首版商保创新药 目录在全国正式实施；1月22日，商务部等9部门联合印发《关于促进药品零售行业高质量发展的意 见》，明确鼓励创新药、参比制剂等进入零售药店销售渠道。一系列新政落地，正从支付、渠道等多维 度重构创新药行业生态，为产业发展注入全新动力。 一次规模扩容 2025年新版国家医保药品目录的调整，堪称医保目录诞生以来创新药规模最大的一次扩容。黄心宇介 绍，本次目录新增114种药品，同步调出29种临床无供应或可被更好替代的药品，新增药品111种为5年 内新上市品种、50种为I类新药，数量与占比均创历年新高。 此次新增的医保药品，均具备填补临床空白、同类疗效更优、性价比突出三大核心特征，精准对接临床 未满足的治疗需求。黄心宇说：" ...

本报讯（记者 柴嵘）2月10日，国家医保局发布医保领域"高效办成一件事"2026年度第一批重点事项清 单，提出今年所有省份开通职工医保个人账户跨省共济，基本实现住院分娩生育医疗费用省内跨统筹区 直接结算。 清单包括：至少开展一批次国家组织药品和高值医用耗材集中带量采购；今年年底前，全国80%的定点 医疗机构实现即时结算；基本实现住院分娩生育医疗费用省内跨统筹区直接结算；所有省份开通职工医 保个人账户跨省共济。 一系列实事将落地。比如，养老机构可通过信息共享办理基本医保参保和变更登记；灵活就业参保人员 可通过信息共享办理基本医保参保和变更登记；全国所有统筹地区实现生育津贴直接发放至个人，无需 经过用人单位中转，提高参保人待遇享受效率和获得感。 ...

在此提醒广大参保群众，提高信息甄别能力，切勿轻信非官方来源的不实信息，谨防个人信息泄露或财 产损失。医保相关政策及业务办理信息，请以河北省医疗保障局及各市医疗保障局官方发布为准。如需 了解更多我省生育保险相关政策内容，可在河北省医疗保障局网站、微信公众号、抖音等官方渠道查 询。 特此公告。 近期，有部分网络用户发布"通过河北智慧医保小程序申请领取500元分娩补贴（助）"相关不实信息， 引发群众关注和咨询。为避免误导公众，维护参保群众合法权益，现就有关情况郑重辟谣如下： 经核实，我省及各市医疗保障局均未出台"分娩补贴（助）"相关政策，也未在官方渠道发布此类宣传报 道。上述网络内容为虚假信息，请勿轻信。河北智慧医保小程序中"生育医疗费用报销"模块用于在省外 住院分娩不能直接结算的参保人进行手工报销申报，"生育津贴申报"模块用于符合享受生育津贴申领条 件的参保人员进行生育津贴申报。 本文转自【河北省医疗保障局】； 河北省医疗保障局2月10日发布"关于网传不实信息的辟谣公告"，全文如下↓ ...

Core Viewpoint - Hainan Haiyao expects a net loss of 350 million to 430 million yuan in 2025 due to intensified market competition and various policy impacts [1] Group 1: Financial Outlook - The company anticipates a net loss ranging from 350 million to 430 million yuan for the year 2025 [1] - Increased depreciation expenses are expected as raw material projects transition to fixed assets [1] - High interest expenses are anticipated due to a large scale of interest-bearing liabilities, which will further impact the company's performance [1] Group 2: Market and Policy Environment - The competitive landscape is expected to intensify due to the influence of medical insurance and centralized procurement policies [1] - The company's innovative drugs have not yet been launched, and newly listed generic drugs have not gained significant market volume [1]

香港联交所最新资料显示，1月29日，大健康国际(02211)股东将股票由粤商国际证券转入香港上海汇丰 银行，转仓市值8551.5万港元，占比14.68%。 大健康国际截至2025年6月30日止年度业绩显示，实现收益约7.115亿元，同比减少34.7%;毛利润约1.134 亿元，同比减少37%;公司拥有人应占亏损2600.6万元，同比盈转亏;每股亏损32.46分。公告称，收益下 降主要是由于受新中国医保政策影响，以及全国性分销网络内的活跃客户数量下降所致。 ...

香港联交所最新资料显示，1月28日，大健康国际(02211)股东将股票由富途证券国际香港转入宝新证 券，转仓市值3035.37万港元，占比5.48%。 大健康国际截至2025年6月30日止年度业绩显示，实现收益约7.115亿元，同比减少34.7%;毛利润约1.134 亿元，同比减少37%;公司拥有人应占亏损2600.6万元，同比盈转亏;每股亏损32.46分。公告称，收益下 降主要是由于受新中国医保政策影响，以及全国性分销网络内的活跃客户数量下降所致。 ...

大健康国际截至2025年6月30日止年度业绩显示，实现收益约7.115亿元，同比减少34.7%;毛利润约1.134 亿元，同比减少37%;公司拥有人应占亏损2600.6万元，同比盈转亏;每股亏损32.46分。公告称，收益下 降主要是由于受新中国医保政策影响，以及全国性分销网络内的活跃客户数量下降所致。 智通财经APP获悉，香港联交所最新资料显示，1月28日，大健康国际(02211)股东将股票由富途证券国 际香港转入宝新证券，转仓市值3035.37万港元，占比5.48%。 ...

智通财经APP获悉，香港联交所最新资料显示，1月20日，大健康国际(02211)股东将股票存入粤商国际 证券，存仓市值3926.79万港元，占比27.54%。 大健康国际截至2025年6月30日止年度业绩显示，实现收益约7.115亿元，同比减少34.7%；毛利润约 1.134亿元，同比减少37%；公司拥有人应占亏损2600.6万元，同比盈转亏；每股亏损32.46分。公告 称，收益下降主要是由于受新中国医保政策影响，以及全国性分销网络内的活跃客户数量下降所致。 ...

Core Viewpoint - The new basic medical insurance drug catalog and commercial insurance innovative drug catalog have been officially implemented as of January 1, 2026, significantly benefiting families of children with growth hormone deficiencies through the inclusion of the long-acting growth hormone Yipeisheng in the insurance coverage, which has seen a price reduction of over 50% [1] Group 1 - The long-acting growth hormone Yipeisheng, developed by Tebao Biopharmaceuticals, is now included in the medical insurance payment scope [1] - The price reduction of over 50% for Yipeisheng, combined with the medical insurance reimbursement policy, will greatly alleviate the financial burden on families of affected children [1] - Yipeisheng has completed the online listing process in all 31 provinces (regions, municipalities) across the country, with new policies being implemented to ensure timely access to the benefits for families [1]

Market Overview - On December 29, the Shanghai Composite Index rose by 0.04%, while the CSI 300 fell by 0.38%. The STAR 50 increased by 0.04%, the CSI 1000 decreased by 0.15%, the ChiNext Index dropped by 0.66%, and the Hang Seng Index declined by 0.71% [4][5]. - The best-performing industries on December 29 were Oil & Petrochemicals (+1.48%), Defense & Military (+1.43%), Banking (+1.03%), Agriculture, Forestry, Animal Husbandry & Fishery (+0.71%), and Automotive (+0.41%). The worst-performing industries included Nonferrous Metals (-1.95%), Utilities (-1.24%), Electric Equipment (-1.13%), Building Materials (-1.11%), and Food & Beverage (-1.06%) [4][5]. - The total trading volume for the entire A-share market on December 29 was 21,577 billion yuan, with net outflow of southbound funds amounting to 3.414 billion HKD [4][5]. Key Recommendations - The report focuses on the company Xingsen Technology (002436), highlighting its comprehensive PCB product system and meticulous process capabilities [6]. - The driving factors for the company include the upgrade of PCB processes driven by AI, leading to an expanding market space. Projected revenues for 2025-2027 are 7,150.01 million yuan, 8,920.01 million yuan, and 11,250.01 million yuan, with growth rates of 22.91%, 24.76%, and 26.12% respectively. Net profits are expected to be 154.57 million yuan, 435.16 million yuan, and 830.26 million yuan, with growth rates of -181.52%, 90.79%, and 90.79% respectively [6][8]. - The catalysts for growth include the AI-driven upgrade of PCB processes [6]. Industry Insights - The pharmaceutical industry is expected to see innovation breakthroughs and favorable policy changes leading to a turning point in the sector's fundamentals. The report notes that the market lacks further catalysts for the pharmaceutical sector [7][9]. - The report emphasizes the potential for continued innovation in drugs and medical devices, driven by improved payment and access policies for innovative drugs and traditional Chinese medicine [9]. - The beauty and personal care industry is characterized by intense competition and increasing differentiation. The report suggests that structural opportunities should be seized, particularly for emerging brands and products [10].